SCHEMBL4492648

SCHEMBL4492648

Cc1ccc(NC(=O)c2c(F)cccc2Cl)cc1OC1CCN(C)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.53
▸ GAA P10253 3/20 0.53
▸ RAB9A P51151 2/20 0.52
▸ NPC1 O15118 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ PTGES O14684 1/20 0.49
▸ KIT P10721 2/20 0.48
▸ CSF1R P07333 1/20 0.48
▸ PDGFRB P09619 1/20 0.48
▸ DDR1 Q08345 1/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.47
▸ MAOB P27338 1/20 0.46
▸ HTR1F P30939 1/20 0.46
▸ P2RX7 Q99572 1/20 0.45
▸ TYK2 P29597 2/20 0.45
▸ MAPK7 Q13164 1/20 0.45
▸ NR1I2 O75469 1/20 0.45
▸ RORA P35398 1/20 0.45
▸ RORC P51449 1/20 0.45
▸ NR1H2 P55055 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10260259 0.92 RAB9A (0.53) MAPTGAARAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL4508333 0.91 RAB9A (0.53) MAPTGAARAB9ANPC1SMN1; SMN2
SCHEMBL10259174 0.88 RAB9A (0.47) RAB9ANPC1SMN1; SMN2HTR1FMAPK7
Hydrochloric Acid SCHEMBL4517763 0.87 RAB9A (0.47) RAB9ANPC1SMN1; SMN2HTR1FMAPK7
SCHEMBL10261970 0.85 GSK3B (0.52) MAPTGAARAB9ANPC1SMN1; SMN2
SCHEMBL4501989 0.85 HTR1F (0.54) KITCSF1RPDGFRBDDR1HTR1F
Hydrochloric Acid SCHEMBL4505402 0.84 GSK3B (0.51) MAPTGAARAB9ANPC1SMN1; SMN2
SCHEMBL4506973 0.82 HTR1F (0.58) MAPTRAB9ANPC1KITCSF1R
SCHEMBL4503643 0.82 P2RX7 (0.52) MAPTGAARAB9ANPC1SMN1; SMN2
SCHEMBL4492168 0.81 HTR1F (0.48) HTR1FP2RX7MAPK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1626958-B1 (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS LILLY CO ELI (US) 2012-06-27 — — EP disclosed
EP-1626958-B1 (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS LILLY CO ELI (US) 2012-06-27 — — EP disclosed
US-7608629-B2 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists ELI LILLY AND COMPANY (US) 2009-10-27 — — US disclosed
US-7608629-B2 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists ELI LILLY AND COMPANY (US) 2009-10-27 — — US disclosed
US-7608629-B2 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists ELI LILLY AND COMPANY (US) 2009-10-27 — — US disclosed
US-20060211734-A1 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists ELILILLY AND COMPANY (US) 2006-09-21 — — US disclosed
EP-1626958-A1 (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS ELI LILLY AND COMPANY (US) 2006-02-22 — — EP disclosed
WO-2004094380-A1 (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2004-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211734-A1 (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists HTR1A, HTR1F, HTR5A MAPT 3174/4885GAA 3880/4885RAB9A 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback